Literature DB >> 28695989

Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.

J R Georgakopoulos1, A Ighani2, L L Zhou3, J Yeung2,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28695989     DOI： 10.1111/jdv.14468

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  7 in total

1.  Interleukin-33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response.

Authors:  Zeyu Chen; Yifan Hu; Yu Gong; Xilin Zhang; Lian Cui; Rongfen Chen; Yingyuan Yu; Qian Yu; Youdong Chen; Hongyue Diao; Jia Chen; Yuanyuan Wang; Yuling Shi
Journal:  Immunology       Date:  2020-05-25       Impact factor: 7.397

2.  Practical experience of secukinumab in the treatment of psoriasis: experience from a single centre.

Authors:  Laoise Griffin; Jennifer Boggs; Bart Ramsay; Caitriona Hackett; Kashif Ahmad; Maeve Lynch
Journal:  Ir J Med Sci       Date:  2020-08-11       Impact factor: 1.568

3.  Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.

Authors:  Antonio Costanzo; Filomena Russo; Marco Galluzzo; Luca Stingeni; Roberta Scuderi; Leonardo Zichichi; Manuela Papini; Luisa Di Costanzo; Andrea Conti; Martina Burlando; Andrea Chiricozzi; Francesca Maria Gaiani; Cristina Mugheddu; Maria Letizia Musumeci; Paolo Gisondi; Stefano Piaserico; Paolo Dapavo; Marina Venturini; Gianluca Pagnanelli; Paolo Amerio; Concetta Potenza; Ketty Peris; Franca Cantoresi; Sara Trevisini; Francesco Loconsole; Annamaria Offidani; Santo Raffaele Mercuri; Viviana Lora; Francesca Prignano; Marta Bartezaghi; Giovanni Oliva; Elisabetta Aloisi; Roberto Orsenigo
Journal:  Acta Derm Venereol       Date:  2021-10-21       Impact factor: 3.875

4.  Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement.

Authors:  Tzong-Yun Ger; Yu-Huei Huang; Rosaline Chung-Yee Hui; Tsen-Fang Tsai; Hsien-Yi Chiu
Journal:  Ther Adv Chronic Dis       Date:  2019-04-17       Impact factor: 5.091

5.  Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records.

Authors:  April W Armstrong; Dhaval Patil; Eugenia Levi; Catherine B McGuiness; Xin Wang; Yi Wang; Chi-Chang Chen; Elizabeth Nguyen; Paul S Yamauchi
Journal:  Dermatol Ther (Heidelb)       Date:  2021-08-28

6.  A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab.

Authors:  Marina Magrey; Michael Bozyczko; Daniel Wolin; Margaret Mordin; Lori McLeod; Eric Davenport; Costel Chirila; Yujin Park
Journal:  Drugs Real World Outcomes       Date:  2019-06

7.  Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis.

Authors:  Maria Concetta Fargnoli
Journal:  Case Rep Dermatol       Date:  2019-09-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.